| Fungal microbiota dysbiosis in IBD H Sokol, V Leducq, H Aschard, HP Pham, S Jegou, C Landman, D Cohen, ... Gut 66 (6), 1039-1048, 2017 | 1218 | 2017 |
| Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases J Kirchgesner, M Lemaitre, F Carrat, M Zureik, F Carbonnel, R Dray-Spira Gastroenterology 155 (2), 337-346. e10, 2018 | 554 | 2018 |
| Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease M Lemaitre, J Kirchgesner, A Rudnichi, F Carrat, M Zureik, F Carbonnel, ... Jama 318 (17), 1679-1686, 2017 | 535 | 2017 |
| ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease T Kucharzik, P Ellul, T Greuter, JF Rahier, B Verstockt, C Abreu, ... Journal of Crohn's and Colitis 15 (6), 879-913, 2021 | 295 | 2021 |
| Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study H Sokol, C Landman, P Seksik, L Berard, M Montil, I Nion-Larmurier, ... Microbiome 8, 1-14, 2020 | 278 | 2020 |
| Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study J Kirchgesner, L Beaugerie, F Carrat, NN Andersen, T Jess, ... Gut 67 (7), 1261-1268, 2018 | 134 | 2018 |
| Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases L Beaugerie, JF Rahier, J Kirchgesner Clinical Gastroenterology and Hepatology 18 (6), 1324-1335. e2, 2020 | 121 | 2020 |
| The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor H Alric, A Amiot, J Kirchgesner, X Tréton, M Allez, Y Bouhnik, L Beaugerie, ... Alimentary pharmacology & therapeutics 51 (10), 948-957, 2020 | 108 | 2020 |
| Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines A Wisniewski, J Kirchgesner, P Seksik, C Landman, A Bourrier, ... United European Gastroenterology Journal 8 (3), 303-313, 2020 | 108 | 2020 |
| High risk of anal and rectal cancer in patients with anal and/or perianal Crohn’s disease L Beaugerie, F Carrat, S Nahon, JD Zeitoun, JM Sabaté, L Peyrin-Biroulet, ... Clinical Gastroenterology and Hepatology 16 (6), 892-899. e2, 2018 | 108 | 2018 |
| Use of proton pump inhibitors in adults in France: a nationwide drug utilization study M Lassalle, T Le Tri, M Bardou, M Biour, J Kirchgesner, F Rouby, ... European journal of clinical pharmacology 76, 449-457, 2020 | 105 | 2020 |
| Therapeutic management of inflammatory bowel disease in real‐life practice in the current era of anti‐TNF agents: analysis of the French administrative health databases 2009–2014 J Kirchgesner, M Lemaitre, A Rudnichi, A Racine, M Zureik, F Carbonnel, ... Alimentary pharmacology & therapeutics 45 (1), 37-49, 2017 | 105 | 2017 |
| Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection H Sokol, S Jegou, C McQuitty, M Straub, V Leducq, C Landman, ... Gut microbes 9 (1), 55-60, 2018 | 101 | 2018 |
| Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases L Beaugerie, J Kirchgesner Clinical Gastroenterology and Hepatology 17 (3), 370-379, 2019 | 98 | 2019 |
| ECCO guidelines on inflammatory bowel disease and malignancies H Gordon, L Biancone, G Fiorino, KH Katsanos, U Kopylov, E Al Sulais, ... Journal of Crohn's and Colitis 17 (6), 827-854, 2023 | 85 | 2023 |
| Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases C Michaudel, C Danne, A Agus, A Magniez, A Aucouturier, M Spatz, ... Gut 72 (7), 1296-1307, 2023 | 80 | 2023 |
| Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study A Amiot, J Filippi, V Abitbol, G Cadiot, D Laharie, M Serrero, R Altwegg, ... Alimentary Pharmacology & Therapeutics 51 (11), 1039-1046, 2020 | 68 | 2020 |
| Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study P Wils, P Seksik, C Stefanescu, S Nancey, M Allez, ... Alimentary Pharmacology & Therapeutics 53 (4), 460-470, 2021 | 67 | 2021 |
| Ustekinumab for perianal Crohn's disease: the BioLAP multicenter study from the GETAID C Chapuis-Biron, J Kirchgesner, B Pariente, Y Bouhnik, A Amiot, ... Official journal of the American College of Gastroenterology| ACG 115 (11 …, 2020 | 61 | 2020 |
| Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study J Kirchgesner, NN Andersen, F Carrat, T Jess, L Beaugerie Gut 69 (5), 852-858, 2020 | 60 | 2020 |
